Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

NCT04993014 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms
HER2-positive Breast Cancer
Circulating Tumor Cell

Interventions

DRUG: Pertuzumab
DRUG: Trastuzumab
OTHER: Circulating tumor cells

Sponsor

AC Camargo Cancer Center